Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Frequencies of HLA-DRB1 in Iranian normal population and in patients with acute lymphoblastic leukemia.

Authors:
Fatemeh Yari Maryam Sobhani Fatemeh Sabaghi Maryam Zaman-Vaziri Nadia Bagheri Ali Talebian

Arch Med Res 2008 Feb 26;39(2):205-8. Epub 2007 Nov 26.

Research Center, Iranian Blood Transfusion Organization, Tehran, Iran.

Background: Recognition of HLA alleles is useful in transplantation and in anthropological and disease studies. Acute lymphoblastic leukemia (ALL) is the most common blood cancer. It is now generally agreed that both genetic and environmental factors play an interactive role in the development of ALL disease. It is unknown whether there exists a restriction to certain MHC genotypes in leukemia like ALL.

Methods: Genetic construct of HLA DRB1 was studied in Iranian normal populations and in patients with acute lymphoblastic leukemia using PCR-SSP method.

Results: It was shown that the most common allele in DRB1 locus in normal population was DRB1*11 (20%), whereas DRB1*09 was the least frequent allele (0.9%). Additionally, this study presented the results of HLA-DRB1 typing in 106 ALL patients and compared them with normal individuals. Comparison of the results between the normal population and the patient group revealed that there was allelic association between the DRB1*13 and the disease. Results showed that the difference between the frequencies of DRB1*13 in patients and normal individuals was significant (p=0.04), but there was a moderate difference among the frequencies of DRB1*04, *07, and *09 in childhood (0-15 years) ALL. The frequencies of DRB1*13, *04, and *07 in patients were 2.5, 16, 4.5% and, in normal individuals, were 11.4, 10, and 8.3%, respectively.

Conclusions: It should be concluded that DRB1*13, which showed a decrease in patients, should be protective against acute lymphoblastic leukemia (ALL), whereas DRB1*04, which was moderately increased in patients, could be considered a susceptible allele for childhood ALL.

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.arcmed.2007.09.009DOI Listing
February 2008

Publication Analysis

Top Keywords

acute lymphoblastic
16
lymphoblastic leukemia
16
normal population
12
normal individuals
12
frequencies drb1*13
8
patients acute
8
difference frequencies
8
iranian normal
8
normal
7
patients
7
leukemia
5
09% additionally
4
drb1*11 20%
4
frequencies
4
patients 45%
4
locus normal
4
20% drb1*09
4
population drb1*11
4
drb1*13 *04
4
drb1 locus
4

Similar Publications

The outcome of Ph-negative acute lymphoblastic leukemia presenting during pregnancy and treated on the Russian prospective multicenter trial RALL-2009.

Authors:
Elena N Parovichnikova Vera V Troitskaya Olga A Gavrilina Andrey N Sokolov Alina V Kokhno Galina A Klyasova Larisa A Kuzmina Gennadiy M Galstyan Sergey A Makhinya Oleg A Latyshkevich Tatyana S Kaporskaya Valery A Lapin Yulia A Chabaeva Sergey M Kulikov Valery G Savchenko

Leuk Res 2021 Feb 14;104:106536. Epub 2021 Feb 14.

National Research Center for Hematology, 125167, Novy Zykovsky proezd, 4, Moscow, Russian Federation.

We report the data on 15 women who presented with Ph-negative acute lymphoblastic leukemia (ALL) between Jan 2009 until Dec 2016 and who were treated on the prospective multicenter RALL-2009 clinical trial. A comparison of their outcome was made with 129 non-pregnant females who entered the study and were treated by the same schedule. 10-years OS for pregnant and non-pregnant women was 58. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Very rare lineage switch from acute myeloid leukemia with BCR-ABL1 to B-lymphoblastic leukemia.

Authors:
Ting Li Hongwei Chen Yun Zhang Yuxiao Zeng Liheng Zheng

Ann Hematol 2021 Mar 5. Epub 2021 Mar 5.

Department of Laboratory Medicine, Chest Hospital of Hebei Province, Shijiazhuang, 050041, China.

View Article and Full-Text PDF
March 2021
Similar Publications

New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.

Authors:
Wan-Tai Wu Wen-Ying Lin Yi-Wei Chen Chun-Fu Lin Hsin-Hui Wang Szu-Hsien Wu Yi-Yen Lee

Int J Mol Sci 2021 Feb 27;22(5). Epub 2021 Feb 27.

School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.

Immunotherapy, including chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, cancer vaccines, and dendritic cell therapy, has been incorporated as a fifth modality of modern cancer care, along with surgery, radiation, chemotherapy, and target therapy. Among them, CAR T-cell therapy emerges as one of the most promising treatments. In 2017, the first two CAR T-cell drugs, tisagenlecleucel and axicabtagene ciloleucel for B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), respectively, were approved by the Food and Drug Administration (FDA). Read More

View Article and Full-Text PDF
February 2021
Similar Publications

A Preliminary Study of FTIR Spectroscopy as a Potential Non-Invasive Screening Tool for Pediatric Precursor B Lymphoblastic Leukemia.

Authors:
Radosław Chaber Aneta Kowal Paweł Jakubczyk Christopher Arthur Kornelia Łach Renata Wojnarowska-Nowak Krzysztof Kusz Izabela Zawlik Sylwia Paszek Józef Cebulski

Molecules 2021 Feb 22;26(4). Epub 2021 Feb 22.

Institute of Physics, College of Natural Sciences, University of Rzeszow, Pigonia 1, 35-310 Rzeszow, Poland.

Early detection of the most common pediatric neoplasm, B-cell precursor lymphoblastic leukemia (BCP-ALL), is challenging and requires invasive bone marrow biopsies. The purpose of this study was to establish new biomarkers for early screening to detect pediatric leukemia. In this small cohort study, Fourier transform infrared (FTIR) spectra were obtained from blood sera of 10 patients with BCP-ALL and were compared with the control samples from 10 children with some conditions other than neoplasm. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

CAR-T Therapy, the End of a Chapter or the Beginning of a New One?

Authors:
Yasser Mostafa Kamel

Cancers (Basel) 2021 Feb 18;13(4). Epub 2021 Feb 18.

School of Cancer & Pharmaceutical Sciences, Faculty of Life & Sciences & Medicine, King's College, London SE1 9NH, UK.

Chimeric antigen receptor-T (CAR-T) therapy targeting CD19 has revolutionised the treatment of advanced acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL). The ability to specifically target the cancer cells has shown high positive results as reported in the registration studies. The success of CAR-T therapy in the first two indications led to the initiation of a large number of studies testing CAR-T therapy in different haematologic tumours such as acute myelogenous leukaemia (AML), Hodgkin's disease (HD), chronic lymphocytic leukaemia (CLL), multiple myeloma (MM), as well as different solid tumours. Read More

View Article and Full-Text PDF
February 2021
Similar Publications